Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (KNSA) is a clinical and commercial-stage biopharmaceutical company pioneering immune-modulating therapies for autoimmune and cardiovascular diseases. This dedicated news hub provides investors, researchers, and healthcare professionals with timely updates on corporate developments and scientific advancements.
Access the most comprehensive collection of Kiniksa news including regulatory milestones, clinical trial results, and strategic partnerships. Our curated feed delivers essential updates on ARCALYST commercialization progress, abiprubart development phases, and pipeline expansion efforts – all critical for informed decision-making in biopharma investing.
Key content categories cover FDA submissions, research collaborations, financial performance, and therapy access initiatives. The centralized format ensures efficient tracking of Kiniksa's progress in addressing complex inflammatory conditions through targeted immune modulation.
Bookmark this page for streamlined monitoring of KNSA's evolving position in autoimmune therapeutics. Verify information accuracy through direct links to official company communications and peer-reviewed clinical data sources.
Kiniksa Pharmaceuticals reported Q4 2022 net product revenue of ARCALYST at $39.9 million and full-year revenue of $122.5 million. For 2023, net product revenue is expected between $190 million and $205 million, indicating over 60% growth from 2022. The average therapy duration was approximately 18 months, with a strong payer approval rate exceeding 90%. Kiniksa maintains cash reserves to support operations through at least 2025. Financially, total revenue for 2022 reached $220.2 million with a net income of $183.4 million, boosted by a significant tax benefit.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call on February 28, 2023, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2022 financial results and recent portfolio execution.
The call will be accessible via a live webcast on Kiniksa's website. Telephone participants must register to receive dial-in details. A replay will be available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for critical unmet medical needs, with assets like ARCALYST and KPL-404 targeting cardiovascular and autoimmune conditions.
Kiniksa Pharmaceuticals (KNSA) reported net product revenue of $39.9 million for Q4 2022 and $122.5 million for full-year 2022. The company's cash reserves of $190.4 million are projected to support operations through 2025. Kiniksa has enrolled 2 of 3 cohorts in the Phase 2 trial of KPL-404 for rheumatoid arthritis, with results expected in 1H 2024. The company aims to grow its cardiovascular franchise through ARCALYST sales and collaborative agreements for mavrilimumab, indicating a focus on strategic portfolio optimization.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET). The presentation will be accessible via a live webcast on the company’s website, with a replay available within approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which aim to address underserved conditions by modulating immunological pathways.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
